Development of an assay for a biomarker of pregnancy and early fetal loss
- PMID: 3319556
- PMCID: PMC1474496
- DOI: 10.1289/ehp.877457
Development of an assay for a biomarker of pregnancy and early fetal loss
Abstract
Human chorionic gonadotropin (hCG) is a glycoprotein hormone, secreted by the syncytiotrophoblast cells of the fertilized ovum, that enters the maternal circulation at the time of endometrial implantation. It is composed of two nonidentical subunits; alpha and beta, with molecular weights of 14 kD and 23 kD, respectively. Its alpha subunit is identical in primary structure to its glycoprotein homologs, luteinizing hormone (LH), follicle-stimulating hormone (FSH), and thyroid-stimulating hormone (TSH). Human chorionic gonadotropin binds to the same receptor as hLH and displays the same biological response, namely, to stimulate the declining function of the corpus luteum to produce progestins and estrogen late in the menstrual cycle. The differences in the structures of hCG and hLH have been exploited to develop antibodies that can measure hCG specifically in the presence of hLH. Two-site antibody binding assays have been developed, based on a surface immunological concept of hCG epitopes, that involve four distinct regions to which antibodies against hCG can bind simultaneously. Antibody cooperative effects, in conjunction with kinetic advantages derived from the concentration factors by use of the sandwich assay technique (immunoradiometric assay, IRMA), have enabled development of extremely sensitive and specific measurement protocols for urinary hCG. The assay described herein permits the detection of pregnancy on an average 25.4 days after the first day of the preceding menses, as opposed to 29.5 days for conventional radioimmunoassay techniques. In addition, the greater sensitivity and specificity of this assay method has permitted the detection of episodes of fetal loss not detected by radioimmunoassay of urine specimens. A large scale epidemiological study is in progress using this assay technique as a way to identify pregnancies that are lost before becoming clinically apparent. This methodology provides a valuable tool for the determination of the rate of early fetal loss.
Similar articles
-
Human chorionic gonadotropin: Different glycoforms and biological activity depending on its source of production.Ann Endocrinol (Paris). 2016 Jun;77(2):75-81. doi: 10.1016/j.ando.2016.04.012. Epub 2016 May 10. Ann Endocrinol (Paris). 2016. PMID: 27177499 Review.
-
Identification of a heterodimer-specific epitope present in human chorionic gonadotrophin (hCG) using a monoclonal antibody that can distinguish between hCG and human LH.J Mol Endocrinol. 2005 Jun;34(3):879-87. doi: 10.1677/jme.1.01683. J Mol Endocrinol. 2005. PMID: 15956355
-
Metabolism of hCG and hLH to multiple urinary forms.Mol Cell Endocrinol. 1996 Dec 20;125(1-2):121-31. doi: 10.1016/s0303-7207(96)03942-1. Mol Cell Endocrinol. 1996. PMID: 9027350 Review.
-
Use of a highly sensitive and specific immunoradiometric assay for detection of human chorionic gonadotropin in urine of normal, nonpregnant, and pregnant individuals.J Clin Endocrinol Metab. 1984 Nov;59(5):867-74. doi: 10.1210/jcem-59-5-867. J Clin Endocrinol Metab. 1984. PMID: 6480810
-
Preparation and characterization of antibodies to the urinary fragment of the human chorionic gonadotropin beta-subunit.Endocrinology. 1988 Jul;123(1):584-93. doi: 10.1210/endo-123-1-584. Endocrinology. 1988. PMID: 2454812
Cited by
-
Synergistic Effect of Human Chorionic Gonadotropin and Granulocyte Colony Stimulating Factor in the Mobilization of HSPCs Improves Overall Survival After PBSCT in a Preclinical Murine Model. Are We Far Enough for Therapy?Stem Cell Rev Rep. 2024 Jan;20(1):206-217. doi: 10.1007/s12015-023-10648-5. Epub 2023 Nov 3. Stem Cell Rev Rep. 2024. PMID: 37922107
-
Maternal steroid levels and the autistic traits of the mother and infant.Mol Autism. 2021 Jul 8;12(1):51. doi: 10.1186/s13229-021-00453-7. Mol Autism. 2021. PMID: 34238355 Free PMC article.
-
Clinical Application for Screening Down's Syndrome by Using Carboxylated Graphene Oxide-Based Surface Plasmon Resonance Aptasensors.Int J Nanomedicine. 2020 Oct 22;15:8131-8149. doi: 10.2147/IJN.S270938. eCollection 2020. Int J Nanomedicine. 2020. PMID: 33144830 Free PMC article.
-
Neutral DNA-avidin nanoparticles as ultrasensitive reporters in immuno-PCR.Analyst. 2020 Jul 21;145(14):4942-4949. doi: 10.1039/d0an00134a. Epub 2020 Jun 5. Analyst. 2020. PMID: 32500871 Free PMC article.
-
Academic College of Emergency Experts in India's INDO-US Joint Working Group and OPUS12 Foundation Consensus Statement on Creating A Coordinated, Multi-Disciplinary, Patient-Centered, Global Point-of-Care Biomarker Discovery Network.Int J Crit Illn Inj Sci. 2014 Jul;4(3):200-8. doi: 10.4103/2229-5151.141398. Int J Crit Illn Inj Sci. 2014. PMID: 25337481 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical